Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases

Paul W. Sperduto, Brian J. Deegan, Jing Li, Krishan R. Jethwa, Paul D. Brown, Natalie Lockney, Kathryn Beal, Nitesh G. Rana, Albert Attia, Chia Lin Tseng, Arjun Sahgal, Ryan Shanley, William A. Sperduto, Emil Lou, Amir Zahra, John M. Buatti, James B. Yu, Veronica Chiang, Jason K. Molitoris, Laura MasucciDavid Roberge, Diana D. Shi, Helen A. Shih, Adam Olson, John P. Kirkpatrick, Steve Braunstein, Penny Sneed, Minesh P. Mehta

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Purpose: To identify prognostic factors, define evolving patterns of care, and the effect of targeted therapies in a larger contemporary cohort of renal cell carcinoma (RCC) patients with new brain metastases (BM). Methods and Materials: A multi-institutional retrospective institutional review board–approved database of 711 RCC patients with new BM diagnosed from January 1, 2006, to December 31, 2015, was created. Clinical parameters and treatment were correlated with median survival and time from primary diagnosis to BM. Multivariable analyses were performed. Results: The median survival for the prior/present cohorts was 9.6/12 months, respectively (P <.01). Four prognostic factors (Karnofsky performance status, extracranial metastases, number of BM, and hemoglobin b) were significant for survival after the diagnosis of BM. Of the 6 drug types studied, only cytokine use after BM was associated with improved survival. The use of whole-brain radiation therapy declined from 50% to 22%, and the use of stereotactic radiosurgery alone increased from 46% to 58%. Nonneurologic causes of death were twice as common as neurologic causes. Conclusions: Additional prognostic factors refine prognostication in this larger contemporary cohort. Patterns of care have changed, and survival of RCC patients with BM has improved over time. The reasons for this improvement in survival remain unknown but may relate to more aggressive use of local brain metastasis therapy and a wider array of systemic treatment options for those patients with progressive extracranial tumor.

Original languageEnglish (US)
Pages (from-to)845-853
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume101
Issue number4
DOIs
StatePublished - Jul 15 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases'. Together they form a unique fingerprint.

Cite this